Ongoing Projects
A Potential Paradigm Shift
in Treatment of Autoimmune Disorders
Survivin Gene Regulation
The survivin gene (BIRC5) is overexpressed in immune cells that evade apoptosis, driving chronic autoimmune activity. Our R&D efforts are dedicated to:
- Downregulating survivin in disease-causing immune cells.
- Restoring immune system balance and eliminating cells responsible for inflammation and tissue damage.
miRNA-Based Therapeutics
We are engineering advanced miRNA-based therapies to target survivin:
- miRNA Design: Identifying and developing miRNAs that specifically suppress survivin expression.
- Precision Delivery: Employing nanoparticle and targeted delivery systems to ensure tissue-specific action and minimize off-target effects.
- Safety Optimization: Ensuring survivin suppression is restricted to pathological immune cells without disrupting normal cellular function.
Broader Applications
Our survivin regulation platform is designed with scalability in mind, offering therapeutic potential for:
- Autoimmune diseases: MS, SSc, RA, lupus, and others.
- Chronic inflammatory conditions: Inflammatory bowel disease, psoriasis, and vasculitis.
- Cancer: Survivin’s role in tumor cell survival makes it a prime target for oncology applications.
Goals of the Initiative
Transformative Therapies:
- Develop first-in-class survivin-targeting miRNA therapeutics.
- Validate therapies in preclinical and clinical trials to bring them closer to patients.
Cutting-Edge R&D:
- Innovate precise, efficient delivery systems to maximize therapy effectiveness and safety.
- Explore new applications for survivin regulation in diseases with unmet medical needs.
Collaboration and Growth:
- Partner with leading academic institutions, biotechnology companies, and healthcare organizations to accelerate development and commercialization.
Global Accessibility:
- Ensure scalability and cost-effectiveness to make survivin-based therapies accessible to patients worldwide.
Progress and Milestones
- Discovery Phase: Identified key miRNAs with high specificity for survivin.
- Preclinical Studies: Demonstrated proof-of-concept in animal models for autoimmune diseases.
- Delivery Systems: Collaborating with experts in nanoparticle and tissue-specific delivery to optimize therapeutic efficacy.
- Regulatory Pathway: Preparing for clinical trial submissions under FDA and international guidelines.
The Impact
At BionovaGenix Inc. (Amorph), we are dedicated to improving the lives of millions of people suffering from autoimmune disorders. By addressing the root cause of these diseases, our survivin-targeting therapies have the potential to:
- Transform treatment paradigms for over 15 million Americans and 50 million people globally living with autoimmune conditions.
- Deliver lasting remission or cures, reducing dependence on lifelong symptom management.
- Establish BionovaGenix as a global leader in next-generation gene-based therapies.
Explore Pharma R&D at Amorph
Discover how we are reshaping the future of healthcare with groundbreaking Dermal filler’s technologies, alongside innovative solutions for autoimmune and infectious diseases and rejuvenation.
